Frequency and causes of vaccine wastage

Setia, Sabeena; Mainzer, Hugh M.; Washington, Michael L.; Coil, Gary; Snyder, Robert E.; Weniger, Bruce G.

doi:10.1016/s0264-410x(01)00433-9

Cited by 86 publications

(46 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,3 In many cases, however, the relevant cold chain is fragile and often not available, especially in underdeveloped regions of the world. 4,5 For this reason, it is critical that vaccine formulations be stabilized to the greatest extent possible.…”

Section: Introductionmentioning

confidence: 99%

Effects of Stabilizers on the Destabilization of Proteins upon Adsorption to Aluminum Salt Adjuvants

Peek

Martin

Nation

et al. 2007

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Effects of Stabilizers on the Destabilization of Proteins upon Adsorption to Aluminum Salt Adjuvants

Peek

Martin

Nation

et al. 2007

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…42 We assumed vaccine wastage was 5%, consistent with the 1% to 5% wastage reported by 92% of Vaccines for Children grantees 43 and the 1.5% to 2.6% wastage rates reported for other injectable vaccines for children. 44 …”

Section: Parameters: Costsmentioning

confidence: 99%

Cost-Effectiveness of Using 2 vs 3 Primary Doses of 13-Valent Pneumococcal Conjugate Vaccine

et al. 2013

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVE: Although effective in preventing pneumococcal disease, 13-valent pneumococcal conjugate vaccine (PCV13) is the most expensive vaccine on the routinely recommended pediatric schedule in the United States. We examined the cost-effectiveness of switching from 4 total doses to 3 total doses by removing the third dose in the primary series in the United States. METHODS: We used a probabilistic model following a single birth cohort of 4.3 million to calculate societal cost savings and increased disease burden from removing the 6-month dose of PCV13. Based on modified estimates of 7-valent pneumococcal conjugate vaccine from randomized trials and observational studies, we assumed that vaccine effectiveness under the 2 schedules is identical for the first 6 months of life and largely similar after administration of the 12- to 15-month booster dose. RESULTS: Removing the third dose of PCV13 would annually save $500 million (in 2011$) but would also result in an estimated 2.5 additional deaths among inpatients with pneumonia or invasive pneumococcal disease. Such dose removal would also result in 261 000 estimated otitis media and 12 000 estimated pneumonia cases annually. These additional illnesses could be prevented through modest increases in coverage. Overall, societal savings per additional life-year lost would be ∼$6 million. When nonfatal outcomes are also considered, savings would range from $143 000 to $4 million per additional quality adjusted life-year lost, depending on the assumptions used for otitis media. CONCLUSIONS: Sizable societal cost savings and a moderate pneumococcal disease increase could be expected from removing the PCV13 primary series’ third dose.

show abstract

“…Exposure of vaccines to excessive heat or freezing temperatures, which often occurs in such settings, can compromise their potency. [1][2][3][4] Although developing countries have maintained cold chain infrastructure since the 1980s, they often find it difficult to power, repair and replace equipment and to transport and store vaccines at the appropriate temperature. 5 Suboptimal vaccine management practices lead to frequent stockouts of critical vaccines and supplies.…”

Section: Perspectivesmentioning

confidence: 99%

Vaccine Presentation and Packaging Advisory Group: a forum for reaching consensus on vaccine product attributes

Mansoor

Kristensen

Meek

et al. 2012

Bull. World Health Organ.

View full text Add to dashboard Cite

Frequency and causes of vaccine wastage

Cited by 86 publications

References 6 publications

Effects of Stabilizers on the Destabilization of Proteins upon Adsorption to Aluminum Salt Adjuvants

Effects of Stabilizers on the Destabilization of Proteins upon Adsorption to Aluminum Salt Adjuvants

Cost-Effectiveness of Using 2 vs 3 Primary Doses of 13-Valent Pneumococcal Conjugate Vaccine

Vaccine Presentation and Packaging Advisory Group: a forum for reaching consensus on vaccine product attributes

Contact Info

Product

Resources

About